🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism

RecruitingNAAges 15 Years - 60 YearsAllChinese Academy of Medical Sciences, Fuwai Hospit…
NCT07328230 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Idiopathic hyperaldosteronism (IHA) represents about 65% of primary hyperaldosteronism cases. Although mineralocorticoid receptor antagonists (MRAs) are the standard first-line treatment, they are often limited by adverse effects. Superselective adrenal artery embolization (SAAE) has been utilized for IHA over the last decade, yet comparative studies against MRAs are lacking. The objective of this study is to compare the safety and efficacy of SAAE and MRA to determine the feasibility of SAAE in treating IHA.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Aged from 15 to 60 with no limits in sex; 2. Patients are diagnosed with primary aldosteronism according to the criteria of the 2016 Endocrine Society guidelines; 3. Sub-typing diagnosis confirmed idiopathic hyperaldosteronism; 4. Patients or their legal representatives have to sign written informed consent approved by the ethics committee. Exclusion Criteria: 1. Unilateral adrenal hyperplasia; 2. Renal insufficiency with an estimated glomerular filtration rate (based on the modification of diet in renal disease criteria) \<45 ml/min/1.73 m², and/or serum creatinine \>176 μmol/L； 3. Hemorrhagic or ischemic stroke, endovascular stent implantation and myocardial infarction within the previous 3 months; 4. Severe contrast agent allergy; 5. Women who are pregnant or planning to become pregnant; 6. Patients with other serious organic diseases cannot tolerate SAAE treatment; 7. Other forms of secondary hypertension.
💊

What it tests

  • Superselective Adrenal Arterial Embolization
  • Spironolactone
📍

Where

3 sites
Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China
Second Affiliated Hospital of Nanchang University
Nanchang, China
The First Affiliated Hospital of Chengdu Medical College
Chengdu, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy